E
Elsa Sanchez-Lopez
Researcher at University of California, San Diego
Publications - 55
Citations - 6109
Elsa Sanchez-Lopez is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Angiotensin II & Inflammation. The author has an hindex of 30, co-authored 48 publications receiving 4544 citations. Previous affiliations of Elsa Sanchez-Lopez include Spanish National Research Council & Autonomous University of Madrid.
Papers
More filters
Journal ArticleDOI
NF-κB Restricts Inflammasome Activation via Elimination of Damaged Mitochondria
Zhenyu Zhong,Atsushi Umemura,Atsushi Umemura,Elsa Sanchez-Lopez,Shuang Liang,Shabnam Shalapour,Jerry Wong,Feng He,Daniela Boassa,Guy Perkins,Syed Raza Ali,Matthew D. McGeough,Mark H. Ellisman,Ekihiro Seki,Ekihiro Seki,Åsa B. Gustafsson,Hal M. Hoffman,Maria T. Diaz-Meco,Jorge Moscat,Michael Karin +19 more
TL;DR: The "NF-κB-p62-mitophagy" pathway is a macrophage-intrinsic regulatory loop through which NF-κBs restrains its own inflammation-promoting activity and orchestrates a self-limiting host response that maintains homeostasis and favors tissue repair.
Journal ArticleDOI
New mitochondrial DNA synthesis enables NLRP3 inflammasome activation
Zhenyu Zhong,Shuang Liang,Elsa Sanchez-Lopez,Feng He,Shabnam Shalapour,Xue Jia Lin,Xue Jia Lin,Jerry Wong,Siyuan Ding,Siyuan Ding,Ekihiro Seki,Bernd Schnabl,Andrea L. Hevener,Harry B. Greenberg,Harry B. Greenberg,Tatiana Kisseleva,Michael Karin +16 more
TL;DR: It is shown that the synthesis of mitochondrial DNA (mtDNA), induced after the engagement of Toll-like receptors, is crucial for NLRP3 signalling, and the dependence on CMPK2 catalytic activity provides opportunities for more effective control ofNLRP3 inflammasome-associated diseases.
Journal ArticleDOI
TGF-β signaling in vascular fibrosis
TL;DR: A better knowledge of the intracellular signals of TGF-β can provide novel therapeutic approaches for fibrotic diseases, and blockers of AngII have demonstrated beneficial effects on many cardiovascular diseases and are now one of the best options to block T GF-β fibrotics responses.
Journal ArticleDOI
Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment
TL;DR: New studies indicate that, in addition to its cell-autonomous anti-tumorigenic functions, autophagy inhibits cancer development by orchestrating inflammation and immunity and should improve the efficacy of cancer immunotherapy.
Journal ArticleDOI
Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy.
Shabnam Shalapour,Joan Font-Burgada,Giuseppe Di Caro,Zhenyu Zhong,Elsa Sanchez-Lopez,Debanjan Dhar,Gerald Willimsky,Massimo Ammirante,Amy Strasner,Donna E. Hansel,Christina Jamieson,Christopher J. Kane,Tobias Klatte,Peter Birner,Lukas Kenner,Michael Karin +15 more
TL;DR: Mouse B cells modulate the response to low-dose oxaliplatin, which promotes tumour-directed CTL activation by inducing immunogenic cell death, and shows that mouse prostate cancer models were refractory to oxali Platin unless genetically or pharmacologically depleted of B cells.